Drug maker Lupin announced last week that its marketing authorization application for a proposed etanercept biosimilar, YLB113, was accepted by the European Medicines Agency.
Drug maker Lupin announced last week that its marketing authorization application for a proposed etanercept biosimilar, YLB113, was accepted by the European Medicines Agency (EMA).
“The application for our etanercept biosimilar and its acceptance in Europe is a significant milestone for our foray into biosimilars in key developed markets. This is also an encouraging development as we continue building our pipeline of higher complexity products,” said Nilesh Gupta, managing director of Lupin, in a statement.
The filing in Europe follows a new drug application for the biosimilar submitted to Japan’s Pharmaceuticals and Medical Devices Agency in March for all indications of the reference product, including adult rheumatoid arthritis (RA) and juvenile idiopathic arthritis.
Earlier this year, Lupin and its partner, Yoshindo Inc., announced the positive results of a global phase 3 clinical trial of the potential etanercept biosimilar. The multinational, randomized, 52-week double-blind controlled trial included more than 500 patients with RA in 11 countries and compared the efficacy of the proposed biosimilar directly with the reference product, Enbrel.
The study met its primary endpoint of equivalent improvement in RA, as measured by the American College of Rheumatology’s criteria for 20% improvement (ACR20). Importantly, the safety and immunogenicity of YLB113 were also similar to those of the reference product.
“Etanercept (YLB113) is the first biosimilar developed in-house by Lupin and this makes us the first Indian pharmaceutical company to file for a complex fusion protein like etanercept in regulated markets,” said Cyrus Karkaria, MD, president of biotechnology at Lupin, in a statement. “This is a significant step to fight against severe auto-immune disorders that call for an effective, affordable equivalent for patients across Europe.”
Lupin has also indicated that it is on track with a plan to file the proposed etanercept biosimilar for FDA regulatory approval in the third quarter of the 2020 fiscal year.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.